A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Del Vecchio Michele
Main Facility: Oncologia medica melanomi
Drug: EIK1001
Pathologies: Melanoma
Randomized clinical study aimed at evaluating the safety, efficacy, and optimal dose of the investigational drug EIK1001 in combination with pembrolizumab in patients with advanced oncological disease.
The study is divided into two parts: an initial dose optimization phase and a subsequent Phase 2/3 confirmatory phase.In the first phase, patients are randomly assigned to three groups: one group receives placebo in combination with pembrolizumab, while the other two groups receive EIK1001 at different dose levels (0.60 mg/m² or 0.75 mg/m²), both in combination with pembrolizumab.
Treatment is administered once weekly until Week 27 and then once every three weeks thereafter.In the second phase, patients receive either placebo or the selected dose of EIK1001 identified in the first phase, always in combination with pembrolizumab, following the same dosing schedule.
Last update: 09/06/2026